Skip to content
value.today
Castle Biosciences Inc. logo

Castle Biosciences Inc.

🇺🇸 Friendswood, Texas, USABiotechnologyFounded 2007
Total raised
$47 M
11 rounds on record
Latest round
$10 M
Jul 2019
First round on record
Mar 2010
Today
Went public
See the company page

Castle Biosciences Inc. is listed today as Castle Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

11 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Castle Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2019$10 MNo. 11$10 to $50 million

Castle Biosciences Inc.: Raise no. 11, Jul 2019

Investors in this round

1 investor had bought by the notice of Jul 30, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernhard E. Spiess · Executive Officer
  • Derek Maetzold · Executive Officer, Director
  • Federico E. Monzon, M.D., FCAP · Executive Officer
  • Frank C. Stokes · Executive Officer
  • Bonnie Anderson · Director
  • Daniel M. Bradbury · Director
  • David C. Kabakoff, Ph.D. · Director
  • G. Bradley Cole · Director
  • Joseph C. Cook, III · Director
  • Mara Aspinall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount includes amounts receivable upon exercise of warrants to purchase shares of Common Stock (assuming no net exercise, where applicable). The warrants have not yet been exercised.”

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Jul 30, 2019. Read the notice at the SEC.

debt, optionsSEC
May 2018$5 MNo. 10$2 to $10 million

Castle Biosciences Inc.: Raise no. 10, May 2018

Investors in this round

44 investors had bought by the notice of Jun 13, 2018: 44 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernhard E. Spiess · Executive Officer
  • Derek Maetzold · Executive Officer, Director
  • Federico E. Monzon, M.D., FCAP · Executive Officer
  • Frank C. Stokes · Executive Officer
  • Bonnie Anderson · Director
  • Daniel M. Bradbury · Director
  • David C. Kabakoff, Ph.D. · Director
  • Joseph C. Cook, Jr. · Director
  • Mara Aspinall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Jun 13, 2018. Read the notice at the SEC.

equitySEC
Jan 2018$5 MNo. 9$2 to $10 million

Castle Biosciences Inc.: Raise no. 9, Jan 2018

Investors in this round

48 investors had bought by the notice of Jan 19, 2018: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernhard E. Spiess · Executive Officer
  • Derek Maetzold · Executive Officer, Director
  • Federico E. Monzon, M.D., FCAP · Executive Officer
  • Frank C. Stokes · Executive Officer
  • Bonnie Anderson · Director
  • Daniel M. Bradbury · Director
  • David C. Kabakoff, Ph.D. · Director
  • Joseph C. Cook, Jr. · Director
  • Mara Aspinall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount includes amounts receivable by the Issuer upon exercise of warrants to purchase the Issuer's Preferred Stock.”

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Jan 19, 2018. Read the notice at the SEC.

equity, optionsSEC
Jul 2015$12 MNo. 8$10 to $50 million

Castle Biosciences Inc.: Raise no. 8, Jul 2015

Investors in this round

17 investors had bought by the notice of Jul 30, 2015: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $20 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director
  • Bonnie Anderson · Director
  • Daniel Bradbury · Director
  • Garheng Kong · Director
  • Joseph Cook, Jr. · Director
  • Mara Aspinall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Jul 30, 2015. Read the notice at the SEC.

equitySEC
Aug 2014$8 MNo. 7$2 to $10 million

Castle Biosciences Inc.: Raise no. 7, Aug 2014

Investors in this round

4 investors had bought by the notice of Aug 18, 2014: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $12 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director
  • Daniel Bradbury · Director
  • Joe Cook, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Aug 18, 2014. Read the notice at the SEC.

equity, optionsSEC
Apr 2014$1 MNo. 6Under $2 million

Castle Biosciences Inc.: Raise no. 6, Apr 2014

Investors in this round

3 investors had bought by the notice of May 5, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director
  • Daniel Bradbury · Director
  • Joe Cook, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed May 5, 2014. Read the notice at the SEC.

equity, debtSEC
Nov 2013$1 MNo. 5Under $2 million

Castle Biosciences Inc.: Raise no. 5, Nov 2013

Investors in this round

3 investors had bought by the notice of Nov 19, 2013: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director, Promoter
  • Daniel Bradbury · Director
  • Joe Cook, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Nov 19, 2013. Read the notice at the SEC.

equity, debtSEC
May 2013$2 MNo. 4Under $2 million

Castle Biosciences Inc.: Raise no. 4, May 2013

Investors in this round

7 investors had bought by the notice of May 16, 2013: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director, Promoter
  • Daniel Bradbury · Director
  • Joe Cook, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed May 16, 2013. Read the notice at the SEC.

equitySEC
Sep 2012$1 MNo. 3Under $2 million

Castle Biosciences Inc.: Raise no. 3, Sep 2012

Investors in this round

10 investors had bought by the notice of Oct 4, 2012: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Oct 4, 2012. Read the notice at the SEC.

equitySEC
Sep 2011$2 MNo. 2Under $2 million

Castle Biosciences Inc.: Raise no. 2, Sep 2011

Investors in this round

4 investors had bought by the notice of Aug 5, 2014: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director
  • Daniel Bradbury · Director
  • Joe Cook, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Aug 5, 2014. Read the notice at the SEC.

equitySEC
Mar 2010$1 MNo. 1Under $2 million

Castle Biosciences Inc.: Raise no. 1, Mar 2010

Investors in this round

6 investors had bought by the notice of Mar 12, 2010: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Castle Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Maetzold · Executive Officer, Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$195,001 of the aggregate offering amount has not and will not be received by the issuer until such time, if any, that the Warrants issued in this transaction are exercised.”

Signed by Derek Maetzold, President and CEO. Source: SEC Form D, newest notice filed Mar 12, 2010. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Castle Biosciences, Inc., its revenue in fiscal 2025 came from these product and service lines: Dermatologic $216.37 million (63%), Non Dermatologic $127.86 million (37%).

    Annual report (SEC XBRL) · Dec 2025

  • Castle Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2019).

    SEC Form D · Jul 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2019

Products and services#

No products or services of Castle Biosciences Inc. are on record.

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in Castle Biosciences Inc.
InvestorKindAmountRoundRoleSource
Bernhard E. SpiessPersonnot statednot statedHeld Series F preferred stock (Form 3, 2019)SEC Form 3
Derek J. MaetzoldPersonnot statednot statedHeld Series A, D, E-2, E-3 and F preferred (Form 3, 2019)SEC Form 3
HealthQuest Venture Management, L.L.C.Venture capitalnot statednot statedHeld Series A, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Joseph C. Cook IIIPersonnot statednot statedHeld Series B, D, E-2, E-3 and F preferred (Form 3, 2019)SEC Form 3
Mara G. AspinallPersonnot statednot statedHeld Series F preferred stock, director (Form 3, 2019)SEC Form 3
MGC Venture Partners 2013 GP, LLCVenture capitalnot statednot statedHeld Series A, D, E-1, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MGC Venture Partners 2013, L.P.Venture capitalnot statednot statedHeld Series A, D, E-1, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MGC Venture Partners 2018 GP, LLCVenture capitalnot statednot statedHeld Series A, D, E-1, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MGC Venture Partners 2018, L.P.Venture capitalnot statednot statedHeld Series A, D, E-1, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MGC Venture Partners QP 2018, L.P.Venture capitalnot statednot statedHeld Series A, D, E-1, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Sofinnova HealthQuest Partners, L.P.Fund or asset managernot statednot statedHeld Series A, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 11 rounds above had up to 48 investors.

Largest shareholders today

Institutions holding Castle Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Castle Biosciences Inc.
NameRoleNamed in
Bernhard E. SpiessExecutive officerJul 2019
Derek MaetzoldExecutive officerJul 2019
Federico E. Monzon, M.D., FCAPExecutive officerJul 2019
Frank C. StokesExecutive officerJul 2019
Bonnie AndersonDirectorJul 2019
Daniel M. BradburyDirectorJul 2019
David C. Kabakoff, Ph.D.DirectorJul 2019
Derek MaetzoldDirectorJul 2019
G. Bradley ColeDirectorJul 2019
Joseph C. Cook, IIIDirectorJul 2019
Mara AspinallDirectorJul 2019
Joseph C. Cook, Jr.DirectorJun 2018
Daniel BradburyDirectorJul 2015
Garheng KongDirectorJul 2015
Joseph Cook, Jr.DirectorJul 2015
Joe Cook, Jr.DirectorAug 2014
Derek MaetzoldPromoterNov 2013

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.